AUTHOR=Gees Maarten , Musch Sara , Van der Plas Steven , Wesse Anne-Sophie , Vandevelde Ann , Verdonck Katleen , Mammoliti Oscar , Hwang Tzyh-Chang , Sonck Kathleen , Stouten Pieter , Swensen Andrew M. , Jans Mia , Van der Schueren Jan , Nelles Luc , Andrews Martin , Conrath Katja TITLE=Identification and Characterization of Novel CFTR Potentiators JOURNAL=Frontiers in Pharmacology VOLUME=9 YEAR=2018 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01221 DOI=10.3389/fphar.2018.01221 ISSN=1663-9812 ABSTRACT=

There is still a high unmet need for the treatment of most patients with cystic fibrosis (CF). The identification and development of new Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators is necessary to achieve higher clinical benefit in patients. In this report we describe the characterization of novel potentiators. From a small screening campaign on F508del CFTR, hits were developed leading to the identification of pre-clinical candidates GLPG1837 and GLPG2451, each derived from a distinct chemical series. Both drug candidates enhance WT CFTR activity as well as low temperature or corrector rescued F508del CFTR, and are able to improve channel activity on a series of Class III, IV CFTR mutants. The observed activities in YFP halide assays translated well to primary cells derived from CF lungs when measured using Trans-epithelial clamp circuit (TECC). Both potentiators improve F508del CFTR channel opening in a similar manner, increasing the open time and reducing the closed time of the channel. When evaluating the potentiators in a chronic setting on corrected F508del CFTR, no reduction of channel activity in presence of potentiator was observed. The current work identifies and characterizes novel CFTR potentiators GLPG1837 and GLPG2451, which may offer new therapeutic options for CF patients.